Neuronetics, Inc.

NASDAQ:STIM

Medical - Diagnostics & Research

Healthcare
$1.25 +0.31%

+$0.00 today

Market cap
$97.16M
Beta
1.04
P/E (TTM)
-2.3
EPS (TTM)
-$0.53
52W Low $0.80High $4.85

Volume 2.55M

Average 2.44M

STIM Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Neuronetics, Inc.NASDAQ: STIM

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation outflow shrinks to $0

Q1 FY2026 stock-based compensation was $0, compared with $1.44M a year earlier. Trailing-twelve-month stock-based compensation was $5.4M. Over 3 fiscal years it compounded at -7.8% a year.

Context

  • Stock-based compensation amounted to 4.6% of revenue in FY2025, down 2.9 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $1.35M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$6.85M+22.2% YoY
LTMMar 2026
$5.4M-5.3% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+22.2%——
3-year CAGR-7.8%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
6.85M USD
Year-over-year change
+22.2%
4-year CAGR
-3.4%

Stock-Based Compensation vs competitors

How STIM compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -5.3% is the 4th highest of 10, against a peer median of -24.7%.
  • Stock-based compensation amounts to 3.6% of revenue for STIM, versus a peer median of 11.1%.
STIM Competitors
Stock-Based Compensation for STIM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ATLNAtlantic International Corp.LTM Dec 2025$36.14M USD-20.0%+420.1%8.3%
OABIOmniAb, Inc.LTM Mar 2026$15.02M USD-24.7%-4.8%52.0%
OSUROraSure Technologies, Inc.LTM Mar 2026$11.45M USD-1.6%-90.4%10.1%
CATXPerspective Therapeutics, Inc.LTM Mar 2026$9.42M USD+38.0%+88.2%1524.4%
CDXSCodexis, Inc.LTM Mar 2026$8.67M USD-29.5%-12.8%11.1%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$7.48M USD-39.0%-34.0%21.6%
PROFProfound Medical Corp.LTM Mar 2026$5.55M USD+98.0%+9.0%29.4%
STIMNeuronetics, Inc.LTM Mar 2026$5.4M USD-5.3%-7.8%3.6%
NYXHNyxoah S.A.LTM Mar 2026€887K EUR-82.2%—5.4%
PREPrenetics Global LimitedLTM Mar 2026$141K USD-98.0%—0.1%
Peer median (excluding STIM) —-24.7%-4.8%11.1%

Competitors are the stored peer set for STIM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(31.19M)(37.16M)(30.19M)(43.73M)(39.14M)
Depreciation & Amortization1.06M1.65M2.01M2.07M3.47M
Deferred Income Tax00000
Stock-Based Compensation7.87M8.75M7.32M5.6M6.85M
Change in Working Capital(6.64M)(5.12M)(14.1M)(6.81M)6.58M
Accounts Receivables(3.05M)(6.66M)(8.83M)(3.73M)3.54M
Inventory(3.44M)(2.59M)(1.1M)3.15M(395K)
Accounts Payables276K(1.97M)2.03M(1.99M)(1.75M)
Other Working Capital(415K)6.1M(6.2M)(4.25M)5.18M
Other Non-Cash Items918K1.14M2.93M11.86M1.87M
Operating Cash Flow(27.98M)(30.74M)(32.04M)(31M)(20.37M)
Capital Expenditures(2.35M)(3.27M)(2.37M)(1.47M)(801K)
Acquisitions (Net)000(2.55M)0
Purchases of Investments00000
Sales of Investments324K000(31K)
Other Investing Activities(7.81M)10M1.05M1.61M31K
Investing Cash Flow(9.84M)6.73M(1.32M)(2.41M)(801K)
Debt Repayment0023.8M(2.52M)9.62M
Common Stock Issued80.97M00026.82M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.03M207K(1.1M)(4.29M)(594K)
Financing Cash Flow83.01M207K22.7M(6.81M)35.85M
Effect of Forex Changes00000
Net Change in Cash45.18M(23.8M)(10.66M)(40.22M)14.68M
Free Cash Flow(30.34M)(34.01M)(34.41M)(32.46M)(21.18M)

Neuronetics, Inc.

NASDAQ:STIM

Intrinsic Alpha fair value

Locked

Current Price

$1.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.